AGA new UC guidance will reshape market access and therapeutic competition, says GlobalData

AGA new UC guidance will reshape market access and therapeutic competition, says GlobalData

The American Gastroenterological Association (AGA) has recently released a major update to its clinical guideline for the pharmacological management of moderate-to-severe ulcerative colitis (UC). The new “living” guideline strongly recommends the early use of biologics and small-molecule therapies following 5-ASA failure, a significant departure from the traditional step-up approach. It marks a turning point in UC treatment strategy, with major …